| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192961 | Annals of Allergy, Asthma & Immunology | 2009 | 8 Pages |
Abstract
This study of baseline characteristics in EXCELS offers a unique opportunity to better understand the history of allergic patients with moderate-to-severe asthma in a real-world treatment setting. This analysis of EXCELS baseline data sets the foundation for long-term assessment of the safety and effectiveness of omalizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Aidan A. MD, James E. MD, Abdelkader MD, Mary K. MS, Mary S. MS, Hassan N. MD, Anthony N. MD, Stephen A. MD, Stanley J. MD,